# OnCo record met-overexpression (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/met-overexpression/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "met-overexpression" ;
  schema:name "c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells)"@en ;
  schema:alternateName "c-Met overexpression"@en, "MET overexpression"@en, "c-Met high"@en, "MET IHC 3+"@en, "c-Met protein overexpression"@en, "MET SP44"@en, "c-Met-high NSCLC"@en ;
  schema:description "c-Met overexpression is a stain, not a gene change: strong (3+) membrane staining in at least half of tumour cells. It selects telisotuzumab vedotin, an antibody-drug conjugate, in previously treated non-squamous lung cancer."@en ;
  schema:url <https://onco.cc/biomarkers/met-overexpression/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc04f980-3957-4e35-ab81-8ec2ffe87215> ;
  onco:tag "biomarker", "met" ;
  onco:related <https://onco.cc/biomarkers/met-ex14/>, <https://onco.cc/biomarkers/met-amplification-readout/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/drugs/telisotuzumab-adizutecan/> ;
  onco:terms <https://onco.cc/terms/ihc/> .